The high P/E ratio is alarming due to unstable growth and below-market forecast. The share price may drop unless medium-term conditions significantly improve. Current prices are deemed unreasonable without a business turnaround.
Despite profitable rise and revenue growth, the weak share performance may call for further inspection of the fundamentals. The share price and annualized TSR loss of 4% over five years hints at investment risks.
Shanghai Hile Bio-Technology Stock Forum
No comment yet